Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ELTX 
Elicio Therapeutics Inc. (ELTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ELTX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.79% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 142.21M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 2 | Beta 2.15 | 52 Weeks Range 4.60 - 12.62 | Updated Date 01/9/2026 |
52 Weeks Range 4.60 - 12.62 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.11 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -79.4% | Return on Equity (TTM) -60013.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 136657292 | Price to Sales(TTM) - |
Enterprise Value 136657292 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.61 | Shares Outstanding 17258652 | Shares Floating 11791297 |
Shares Outstanding 17258652 | Shares Floating 11791297 | ||
Percent Insiders 36.77 | Percent Institutions 11.93 |
Upturn AI SWOT
Elicio Therapeutics Inc.
Company Overview
History and Background
Elicio Therapeutics Inc. is a clinical-stage immunotherapy company focused on developing novel treatments for cancer. Founded in 2019, it emerged from the research labs of the Broad Institute and Dana-Farber Cancer Institute. The company's platform is built around AMPs (adjuvanted mRNA therapeutics) designed to elicit potent and targeted immune responses against solid tumors. Key milestones include the advancement of its lead candidates into clinical trials.
Core Business Areas
- AMP Platform: Elicio Therapeutics utilizes its proprietary AMP platform, which combines mRNA technology with potent adjuvants to stimulate immune cells and direct them to tumor sites. This platform aims to overcome the challenges of treating solid tumors with immunotherapies.
- Oncology Therapeutics: The company's primary focus is on developing and commercializing novel immunotherapies for various types of solid tumors, with an emphasis on those that are currently difficult to treat.
Leadership and Structure
Elicio Therapeutics is led by a management team with extensive experience in drug development, oncology, and biotechnology. The organizational structure is typical of a clinical-stage biopharmaceutical company, with specialized departments for research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- EL-200: EL-200 is Elicio's lead investigational product, an AMP-based immunotherapy designed to target KRAS-mutated solid tumors. It is currently in clinical trials for indications such as non-small cell lung cancer (NSCLC) and pancreatic cancer. Competitors in this space include companies developing targeted therapies and other immunotherapies for KRAS-mutated cancers. Specific market share data for EL-200 is not yet available as it is in clinical development.
- EL-201: EL-201 is another AMP-based immunotherapy candidate being developed for specific oncogenic drivers and tumor types. Like EL-200, it is in early-stage clinical development. Market share data is not applicable at this stage.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly dynamic and competitive, driven by significant unmet needs and ongoing scientific advancements. Immunotherapies, in particular, have revolutionized cancer treatment, but challenges remain in treating certain solid tumors and overcoming resistance mechanisms. The mRNA technology space is also rapidly evolving.
Positioning
Elicio Therapeutics is positioned as an innovative player in the immunotherapy space, leveraging its unique AMP platform to address previously untreatable solid tumors. Its competitive advantage lies in its novel technology designed to elicit strong, localized immune responses.
Total Addressable Market (TAM)
The total addressable market for solid tumor immunotherapies is in the hundreds of billions of dollars globally. Elicio Therapeutics aims to capture a significant portion of this market by developing therapies for specific, high-need patient populations.
Upturn SWOT Analysis
Strengths
- Proprietary AMP platform technology
- Experienced management team
- Focus on unmet needs in solid tumors
- Strong scientific backing
Weaknesses
- Early-stage clinical development (no approved products)
- Reliance on successful clinical trial outcomes
- Significant capital requirements for R&D
Opportunities
- Expanding pipeline of AMP candidates
- Partnerships with larger pharmaceutical companies
- Advancements in cancer research and diagnostics
- Growing acceptance of mRNA-based therapeutics
Threats
- Clinical trial failures
- Competition from established and emerging immunotherapy companies
- Regulatory hurdles
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- Moderna (MRNA)
- BioNTech SE (BNTX)
- Allogene Therapeutics (ALLO)
- Caribou Biosciences (CRBU)
Competitive Landscape
Elicio Therapeutics faces intense competition from established pharmaceutical companies and innovative biotech firms in the highly competitive oncology and immunotherapy markets. Its ability to differentiate through its AMP platform and demonstrate clinical efficacy will be crucial for success.
Growth Trajectory and Initiatives
Historical Growth: Elicio Therapeutics has experienced growth in its operational capacity and pipeline advancement since its founding in 2019, moving from early-stage research to clinical development.
Future Projections: Future projections are contingent on the success of its clinical trials and the potential commercialization of its product candidates. Analyst projections for companies at this stage are highly speculative and dependent on regulatory and clinical outcomes.
Recent Initiatives: Recent initiatives likely include the progression of EL-200 and EL-201 into and through their respective clinical trials, potential strategic collaborations, and ongoing platform development.
Summary
Elicio Therapeutics is an early-stage immunotherapy company with a promising AMP platform for solid tumors. Its strengths lie in its innovative technology and experienced team. However, it faces significant risks due to its clinical-stage status and reliance on trial success. Future success hinges on navigating clinical and regulatory hurdles while fending off strong competition in the oncology space.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and official statements
- Industry analysis reports
- Scientific publications
Disclaimers:
This JSON output is a synthesized analysis based on publicly available information and general industry knowledge. It is not financial advice and should not be used for investment decisions. The company may not be publicly traded or may have limited publicly available financial data. Market share data for early-stage companies is often speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elicio Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-02-05 | CEO, President & Director Mr. Robert T. Connelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://elicio.com |
Full time employees 32 | Website https://elicio.com | ||
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.